The problem with some of cancer’s most important signaling pathways is that healthy cells need them, too. A drug that shuts down the wrong biological switch can injure the tissue it is meant to protect.
That tension sits at the center of ST316, an investigational peptide from Sapience Therapeutics designed to interfere with the interaction between beta-catenin and BCL9, a partnership associated with abnormal Wnt signaling in certain tumors. The company announced a regulatory development for a new indication in September 2026. It is not an announcement of an approved treatment.
Why Familial Adenomatous Polyposis Needs New Treatments
On September 14, Sapience said the U.S. Food and Drug Administration had accepted an investigational new drug application for ST316 in familial adenomatous polyposis, or FAP.
FAP is an inherited disorder, typically associated with mutations in the APC gene, that causes numerous colorectal polyps and a substantially elevated lifetime risk of colorectal cancer. Without appropriate intervention, that risk can become extremely high.
Patients and clinicians already face difficult surveillance and treatment decisions. Management frequently involves repeated endoscopic monitoring and preventive surgery.
A medicine that could alter the disease process would be consequential, particularly if it reduced polyp burden or recurrence. But permission to investigate a medicine does not establish that it works.
How ST316 Targets the Beta-Catenin and BCL9 Interaction
ST316 belongs to Sapience Therapeutics’ class of stabilized peptides designed to engage intracellular protein interactions that have historically been difficult to target with conventional drugs.
Its proposed mechanism focuses on the interaction between beta-catenin and BCL9, a transcriptional co-activator associated with oncogenic Wnt signaling.
The theoretical attraction is selectivity: interrupt a disease-driving transcriptional program while preserving more of the signaling necessary for normal tissues.
This distinction matters because the Wnt/beta-catenin pathway participates in normal intestinal tissue renewal and bone homeostasis. Broadly suppressing the pathway can therefore create unwanted biological effects.
Sapience designed ST316 to interfere more selectively with oncogenic beta-catenin activity. That is a compelling scientific hypothesis, but it is not yet a demonstrated long-term clinical safety advantage in people with FAP.
What Early Colorectal Cancer Results Actually Show
Before expanding development toward FAP, Sapience evaluated ST316 in a Phase 1/2 clinical program involving patients with advanced solid tumors, including metastatic colorectal cancer.
At the American Association for Cancer Research Annual Meeting in April 2026, the company reported early results from a Phase 2 expansion cohort involving 15 patients receiving ST316 in combination with standard-of-care FOLFIRI chemotherapy and bevacizumab.
Based on an April 13, 2026 data cutoff, seven of the 15 patients had confirmed partial responses, corresponding to an objective response rate of approximately 47%. Disease control was reported in 14 of the 15 patients.
Those findings warrant further investigation, but their limitations are substantial. This was a small combination-treatment cohort without a randomized concurrent control group. Comparisons with historical treatment results cannot establish how much additional benefit ST316 contributed.
The safety picture also requires careful interpretation. The company reported no dose-limiting toxicities in its Phase 1 monotherapy program. Clinical abstracts from the broader program nevertheless described adverse events including liver enzyme elevations and neutropenia in patients receiving combination therapy.
Most importantly, metastatic colorectal cancer and FAP represent different clinical populations. Tumor responses in patients with advanced cancer cannot automatically be translated into prevention or reduction of precancerous polyps.
What the Planned Phase 1b FAP Trial Will Measure
The FAP investigation has a registered clinical-trial design rather than simply an undefined future research plan.
The study, identified as NCT07729371, is designed as an open-label Phase 1b trial involving approximately 40 adults with familial adenomatous polyposis who have previously undergone colectomy and have recurrent polyps.
Its planned assessments include treatment-related adverse events, safety and tolerability, drug exposure, pharmacodynamic measurements and changes in colorectal or pouch polyp burden.
According to the accessible registry record, the study was listed as not yet recruiting, with an estimated start date of January 4, 2027. That is a planned date, not confirmation that enrollment has begun.
The absence of a randomized placebo comparison in this early study will matter when interpreting results. Changes in polyp burden may offer a useful preliminary signal, but stronger controlled evidence would be needed to establish a treatment effect reliably.
The fundamental question is whether interfering with beta-catenin/BCL9 signaling can safely reduce clinically meaningful polyp burden without compromising normal tissue functions.
Why Intracellular Peptide Delivery Remains Difficult
The peptide’s route to the inside of a cell is itself part of the scientific challenge.
Protein-protein interfaces can be broad, dynamic and difficult for conventional small molecules to engage. Peptides may offer a larger contact surface, but their stability, tissue distribution and cellular uptake must be engineered carefully.
Even when a compound blocks its intended target in laboratory models, the clinical question remains whether enough active drug reaches the relevant tissue without unacceptable effects elsewhere.
Sapience has reported supportive preclinical findings in FAP models and early clinical evidence of activity against the targeted signaling pathway in cancer studies.
Those findings provide a rationale for continued research. They do not establish that ST316 will prevent polyps, avoid surgery or reduce colorectal cancer risk in people with FAP.
Regulatory Clearance Is Not Proof of a Treatment Breakthrough
The regulatory vocabulary matters.
Acceptance or clearance of an investigational new drug application allows clinical investigation to proceed under the applicable regulatory framework. Orphan-drug designation can provide development incentives for therapies targeting rare diseases.
Neither milestone is FDA marketing approval, and neither proves clinical efficacy.
The peptide industry frequently compresses those stages into the word “breakthrough.” In this case, the more compelling story is the attempt to reach a previously difficult intracellular target in a disease with a clear unmet medical need.
If ST316 eventually demonstrates clinically meaningful benefit in FAP, the implications could extend beyond one hereditary disorder to the broader strategy of targeting protein interactions with engineered peptides.
If it fails, the trial may still teach developers where the selectivity or delivery hypothesis breaks down. Either outcome would be more informative than treating the start of a regulatory pathway as a therapeutic victory.
Sources and Further Reading
- Sapience Therapeutics: FDA Acceptance of ST316 IND for FAP, September 14, 2026
- Sapience Therapeutics: Initial Phase 2 ST316 Colorectal Cancer Results, April 20, 2026
- ClinicalTrials.gov: ST316 Phase 1b Familial Adenomatous Polyposis Study (NCT07729371)
- ClinicalTrials.gov: ST316 Advanced Solid Tumor Study (NCT05848739)
